Search

ISIS 104838

ISIS 104838 is under investigation in clinical trial NCT00048321 (ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis).

PRX-OTC

PRX-OTC is an intracellular enzyme replacement therapy designed to replace missing or defective enzyme in patients with ornithine transcarbamylase deficiency.

SPL23-2

SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of cystic fibrosis.[L46767]

TTX-MC138

TTX-MC138 is an antisense oligonucleotide targeting miR-10b.[L48335] It is under investigation for the treatment of various metastatic cancers.

ISF402

ISF402 is an investigational peptide tetramer which helps dispersal of insulin via zinc chelation, therefore allowing insulin hexamers to break free.

Milveterol

GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.

Daridorexant

Daridorexant was designed via an intensive drug discovery program to improve the potency and maximize the duration of action while minimizing next-morning residual activity. … Novel drugs that target orexin receptors gained increasing attention after discovering the role of orexin signalling pathway in wakefulness and [almorexant], an orexin receptor antagonist that improved

Talizumab

TNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.

ACY001

Dichloroacetic acid

Dichloroacetic acid, often abbreviated DCA, is an acid analogue of acetic acid in which two of the three hydrogen atoms of the methyl group have been replaced by chlorine atoms.